Format

Send to

Choose Destination
Cancer Gene Ther. 2002 Dec;9(12):1062-7.

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider.

Author information

1
Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

PMID:
12522445
DOI:
10.1038/sj.cgt.7700548
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center